Femasys (FEMY) announced a significant initial order valued at approximately $500,000 USD for the commercial launch of FemBloc Permanent Birth Control in France and the Benelux region through its partnership with leading distributor Kebomed. Following the Company’s recent entry into Spain, this order marks continued progress in expanding FemBloc’s presence across key European markets and reflects growing international momentum for this innovative, non-surgical permanent contraceptive solution.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FEMY:
- Femasys Secures $12 Million Through Private Placement
- Femasys Receives FDA Approval for FemBloc Trial
- Femasys secures FDA approval to advance final FemBloc trial phase
- Femasys, Inc. Advances Non-Surgical Birth Control with FemBloc Study
- Femasys announces initiation of post-market surveillance study for FemBloc